NCT07214064View on ClinicalTrials.gov

Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

August 31, 2027

Study Completion Date

December 31, 2027

Conditions
AML (Acute Myeloid Leukemia)MDS/AMLMDS (Myelodysplastic Syndrome)
Interventions
DRUG

RIC regimen

Venetoclax (Venclyxto®): 400 mg abs./d day -8 to -2, Fludarabine 30 mg/m2 BSA day -6 to day -2, Treosulfan 10 g/m2 BSA day -4 to day -2

Trial Locations (1)

72076

University Hospital , Department of Internal Medicine II, Tübingen

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER